CLDX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

CL

Mkt Cap

$2.16B

Volume

779.27K

Next Earnings

November 9th

Loading chart

CL

CLDXCelldex Therapeutics, Inc

CLDX

Pay with—

Available Balance0.00

CL

Mkt Cap

$2.27B

Volume

779.27K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and VaxcyteFour biotech companies—Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics, and Vaxcyte—are approaching significant clinical trial readouts in fall 2026 that could materially impact their valuations. Kodiak will report phase III data for wet AMD treatments, Celldex expects CSU study results, Rapport targets bipolar mania trial outcomes, and Vaxcyte will release pneumococcal vaccine data. These mid- to late-stage readouts represent major catalysts for clinical-stage companies.Zacks Investment Research · Sep 23, 2026

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual MeetingCelldex announced positive long-term Phase 2 results for barzolvolimab in chronic spontaneous urticaria (CSU), showing that up to 64% of patients remained angioedema-free seven months after treatment completion. The drug demonstrated rapid, significant, and durable improvements in angioedema symptoms, with potential to shift CSU treatment from symptom control to disease modification. Two Phase 3 trials enrolling 1,939 patients are ongoing with topline data expected in Q4 2026.GlobeNewswire Inc. · Jun 14, 2026

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual MeetingCelldex announced positive Phase 1 results for CDX-622, a novel bispecific antibody targeting soluble SCF and TSLP for inflammatory diseases. The drug demonstrated rapid, dose-dependent reductions in serum tryptase indicative of mast cell depletion and was well-tolerated at all dose levels. CDX-622 is now being studied in Phase 1b for mild to moderate asthma, with plans for additional proof-of-concept studies in allergic rhinitis and food allergy.GlobeNewswire Inc. · Jun 14, 2026

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesCelldex Therapeutics successfully closed an underwritten public offering of 11,896,750 shares of common stock at $29.00 per share, generating approximately $345 million in gross proceeds. The underwriters exercised their full option to purchase an additional 1,551,750 shares. The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor as joint bookrunning managers.GlobeNewswire Inc. · Apr 6, 2026

Celldex Announces Pricing of $300 Million Public Offering of Common StockCelldex Therapeutics priced an underwritten public offering of 10.3 million shares at $29.00 per share, expecting to raise approximately $300 million in gross proceeds. The company plans to use the funds for commercial readiness and launch of barzolvolimab for CSU treatment, clinical development of product candidates, and expansion of its bispecific antibody platform.GlobeNewswire Inc. · Apr 2, 2026

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026Celldex presented Phase 2 data showing barzolvolimab retreatment achieves similar efficacy to initial treatment in cold urticaria and symptomatic dermographism patients, with 62% and 60% complete response rates respectively. The data supports an intermittent treatment paradigm and barzolvolimab's profile as a first-in-class therapy. Phase 3 trials (EMBARQ-ColdU and SD) are currently enrolling patients.GlobeNewswire Inc. · Mar 1, 2026

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026Celldex presented positive Phase 2 data for barzolvolimab, a novel mast cell-targeting monoclonal antibody, showing sustained off-treatment efficacy in chronic spontaneous urticaria (CSU) with 71% of patients achieving complete response after 52 weeks of treatment and 50% maintaining complete response 7 months post-treatment. The company also demonstrated improved quality of life and urticaria control in cold urticaria and symptomatic dermographism patients. Phase 3 enrollment in CSU was completed six months ahead of schedule with topline data expected in Q4 2026.GlobeNewswire Inc. · Feb 27, 2026

Chronic Inducible Urticaria (CIndU) Market Research Report 2025-2035 | Competitive Analysis of AstraZeneca, Celldex Therapeutics, J&J, Merck, Novartis, Pfizer, Regeneron Pharma, Sanofi, Sun PharmaThe global CIndU market is experiencing significant growth driven by advancements in diagnostic tools, biologic therapies, and increasing awareness of immune mechanisms, with emerging personalized medicine approaches promising improved patient outcomes.GlobeNewswire Inc. · Aug 27, 2025

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025Celldex's barzolvolimab demonstrated rapid, robust, and durable improvements in angioedema symptoms over 52 weeks in a Phase 2 study for chronic spontaneous urticaria, with up to 77% of patients being angioedema-free at Week 52.GlobeNewswire Inc. · Jun 14, 2025

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025Celldex Therapeutics presented positive preclinical data for its bispecific antibody CDX-622, which targets TSLP and SCF to reduce inflammation and fibrosis. The data showed CDX-622 inhibits TSLP and SCF-dependent activities, and a Phase 1 study in healthy volunteers is ongoing.GlobeNewswire Inc. · Mar 3, 2025

to start trading

CL

CLDXCelldex Therapeutics, Inc

CLDX

Pay with—

Available Balance0.00

Your PositionYou don't own any CLDX yet.

Related Tickers

Earnings